A Pharmacodynamic Study of a Personalized Strategy for P2Y12 Inhibition Versus Ticagrelor in Reducing Ischemic and Bleeding Risk
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.
Also called NCT02044146
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 120 participants
- Registry
-
NCT02044146
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Canada
- Registry status
- Completed
Technical summary
Registry record NCT02044146. Randomized; double masking; primary purpose treatment. Start 2014-09 (registry gives no type); primary completion 2016-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Pharmacodynamic Study of a Personalized Strategy for P2Y12 Inhibition Versus Ticagrelor in Reducing Ischemic and Bleeding Risk
- Acronym
- RAPID MANAGE
- Condition
- Acute Coronary Syndrome
- Condition
- Percutaneous Coronary Intervention
- Intervention (Drug)
- Ticagrelor, Prasugrel, Clopidogrel
- Lead sponsor
- Ottawa Heart Institute Research Corporation
- Collaborator
- Canadian Institutes of Health Research (CIHR)
Record details
- Record id
cardio:ct-nct02044146- Content hash
e4855bdc8bac6cbc53adc6da0712df89102ce8d024ff30e9904438de04f70756